Structure Therapeutics Inc. (NASDAQ:GPCR) Receives Average Recommendation of "Buy" from Analysts

Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) has been assigned a consensus recommendation of "Buy" from the eight research firms that are covering the stock, Marketbeat reports. Eight analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have issued a report on the stock in the last year is $81.29.

Several equities research analysts have weighed in on GPCR shares. HC Wainwright restated a "buy" rating and set a $80.00 price target on shares of Structure Therapeutics in a report on Thursday, December 19th. Morgan Stanley started coverage on shares of Structure Therapeutics in a research note on Monday, September 23rd. They set an "overweight" rating and a $118.00 target price on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, September 23rd. JMP Securities reissued a "market outperform" rating and issued a $91.00 price objective on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Finally, Stifel Nicolaus began coverage on shares of Structure Therapeutics in a research report on Wednesday. They set a "buy" rating and a $50.00 price objective for the company.

Structure Therapeutics Stock Performance

Shares of Structure Therapeutics stock traded down $0.14 during trading hours on Thursday, reaching $27.04. 837,138 shares of the company were exchanged, compared to its average volume of 578,436. The firm has a market cap of $1.55 billion, a PE ratio of -36.54 and a beta of -2.78. The stock's fifty day moving average is $32.35 and its 200 day moving average is $36.63. Structure Therapeutics has a 1 year low of $25.90 and a 1 year high of $62.74.

Hedge Funds Weigh In On Structure Therapeutics

Several hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC raised its position in Structure Therapeutics by 4,155.6% in the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock valued at $31,000 after purchasing an additional 1,122 shares during the last quarter. Sandia Investment Management LP purchased a new stake in shares of Structure Therapeutics in the second quarter valued at about $39,000. Assetmark Inc. boosted its stake in shares of Structure Therapeutics by 120.0% during the third quarter. Assetmark Inc. now owns 1,318 shares of the company's stock worth $58,000 after buying an additional 719 shares during the period. Quarry LP purchased a new position in shares of Structure Therapeutics during the second quarter worth about $79,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Structure Therapeutics by 60.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company's stock worth $158,000 after buying an additional 1,420 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.